

# Surgical Trial In Traumatic intraCerebral Haemorrhage

<b>Submission date</b> 19/03/2009	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 27/03/2009	<b>Overall study status</b> Completed	<input checked="" type="checkbox"/> Protocol
<b>Last Edited</b> 09/09/2015	<b>Condition category</b> Injury, Occupational Diseases, Poisoning	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Barbara A Gregson

**Contact details**  
Neurosurgical Trials Unit  
Newcastle University  
3-4 Claremont Terrace  
Newcastle upon Tyne  
United Kingdom  
NE2 4AE  
-  
trauma.stitch@ncl.ac.uk

## Additional identifiers

**Protocol serial number**  
HTA 07/37/16; 1.0

## Study information

**Scientific Title**  
Surgical Trial In Traumatic intraCerebral Haemorrhage: an international multi-centre pragmatic randomised parallel group trial

**Acronym**

STITCH (Trauma)

**Study objectives**

A policy of early surgery in patients with traumatic intracerebral haemorrhage will improve outcome at six months compared to a policy of initial conservative treatment.

More details can be found at: <http://www.nets.nihr.ac.uk/projects/hta/073716>

As of 27/03/2009, the list of countries is not yet finalised. Other countries from Africa, Asia, Australasia, Europe, and North and South America are planned to be included.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Submission pending as of 19/03/2009

**Study design**

International multi-centre pragmatic randomised parallel-group trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Traumatic intracerebral haemorrhage and contusion

**Interventions**

Early surgery vs initial conservative treatment

**Intervention Type**

Procedure/Surgery

**Primary outcome(s)**

Unfavourable outcome will be death or severe disability which will be defined using a prognosis based 8 point Glasgow Outcome Scale.

Total duration of follow-up: 6 months

**Key secondary outcome(s)**

The following will be assessed at 6 and 12 months:

1. Rankin scale
2. Euroqol EQ-5D
3. Mortality
4. Survival
5. Major Adverse Events (death, pulmonary embolism or deep vein thrombosis, infection, rehaemorrhage)

6. Quality-adjusted life-years (QALYs)
7. Total health care costs
8. Social costs

**Completion date**

28/02/2014

## Eligibility

**Key inclusion criteria**

1. Both males and females, adults aged 14 or over
2. Evidence of a traumatic intracerebral haemorrhage (TICH) on computed tomography (CT) with a single volume of attenuation significantly raised above that of the background white and grey matter that is in total greater than 10 ml calculated by width times height times length in cm divided by 2
3. Within 24 hours of head injury
4. Clinical equipoise: only patients for whom the responsible neurosurgeon is uncertain about the benefits of either treatment are eligible

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. A significant surface haematoma (epidural haematoma [EDH] or subdural haematoma [SDH]) requiring surgery (The indications for intervention for these patients are already very well defined)
2. More than two separate haematomas fulfilling inclusion criteria
3. If surgery can not be performed within 36 hours of injury or 12 hours of randomisation (whichever is the shorter)
4. Severe pre-existing physical or mental disability or severe co-morbidity which might lead to a poor outcome even if the patient made a full recovery from the head injury (Examples would be a high level of dependence before the injury or severe irreversible associated injury such as complete spinal cord injury)
5. Permanent residence outside a study country preventing follow up
6. Patient and/or relative has a strong preference for one treatment modality

**Date of first enrolment**

01/09/2009

**Date of final enrolment**

28/02/2014

# Locations

## Countries of recruitment

United Kingdom

England

Czech Republic

Egypt

Germany

Greece

India

Italy

Latvia

Lithuania

North Macedonia

Poland

Russian Federation

Spain

United States of America

## Study participating centre

**Newcastle University**

Newcastle upon Tyne

United Kingdom

NE2 4AE

# Sponsor information

## Organisation

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)

**ROR**

<https://ror.org/05p40t847>

# Funder(s)

## Funder type

Government

## Funder Name

Health Technology Assessment Programme

## Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2015		Yes	No
<a href="#">Results article</a>	results	01/09/2015		Yes	No
<a href="#">Protocol article</a>	protocol	16/10/2012		Yes	No